Dictyostelium discoideum phenylalanine hydroxylase (DicPAH; residues 1-415) was expressed in Escherichia coli and purified for structural analysis. Apo DicPAH and DicPAH complexed with dihydrobiopterin (BH 2 ) and Fe III were crystallized using 0.06 M PIPES pH 7.0, 26%(w/v) PEG 2000 by the hangingdrop vapour-diffusion method. Crystals of apo DicPAH and the DicPAH-BH 2 -Fe III complex diffracted to 2.6 and 2.07 Å resolution, respectively, and belonged to space group P2 1 , with unit-cell parameters a = 70.02, b = 85.43, c = 74.86 Å , = 110.12 and a = 70.97, b = 85.33, c = 74.89 Å , = 110.23 , respectively. There were two molecules in the asymmetric unit. The structure of DicPAH has been solved by molecular replacement.
Introduction
The nonhaem iron-dependent enzyme phenylalanine hydroxylase (PAH; EC 1.14.16.1) catalyzes the hydroxylation of the aromatic amino acid l-phenylalanine (l-Phe) to l-tyrosine (l-Tyr) in the presence of the specific cofactor tetrahydrobiopterin (BH 4 ) and dioxygen (O 2 ). As l-Tyr is the precursor of the neurotransmitter dopamine, the catabolism of l-Phe plays an essential role in the development of the neural system (Kaufman, 1993) . Disorder of the PAH system leads to the diseases phenylketonuria and hyperphenylalaninaemia, which result in brain-development problems unless treated immediately after birth (Scriver & Kaufman, 1995) . Fulllength mammalian PAHs consist of three domains: an N-terminal regulatory domain, a central catalytic domain and a short C-terminal oligomerization domain for tetramer formation. The catalytic site includes a nonhaem Fe atom coordinated by a His-His-Glu catalytic triad that is highly conserved in aromatic amino-acid hydroxylases. Dysfunction of human PAH is mostly caused by mutations that are found in the catalytic domain. These mutations demonstrate different clinical, metabolic and enzymatic phenotypes (Erlandsen et al., 2004) . Crystallographic studies of human and rat PAHs revealed the binding sites of the pterin cofactor and the substrate, and provided insights into the substrate-specificity and catalytic mechanism of the enzyme (Erlandsen et al., 1997; Fusetti et al., 1998; Kobe et al., 1999) . Mammalian PAH responds with positive cooperativity to increased concentration of the substrate (Kaufman, 1993; Knappskog et al., 1996) .
There are four possible BH 4 stereoisomers: l-erythro-BH 4 , l-threo-BH 4 , d-erythro-BH 4 and d-threo-BH 4 . l-erythro-BH 4 is ubiquitous in animals as the natural cofactor for aromatic amino-acid hydroxylases, whereas the social amoeba Dictyostelium discoideum produces both l-erythro-BH 4 and d-threo-BH 4 (DH 4 ; Klein et al., 1990; Cho et al., 1999) . Interestingly, Dictyostelium PAH (DicPAH) uses both as cofactors, although it exhibits higher activity with DH 4 than with l-erythro-BH 4 (Siltberg-Liberles et al., 2008) . This indicates that DicPAH possesses dual cofactor specificity (Choi et al., 2005) . However, no structural information is available on the binding of DH 4 to PAH. In order to understand the enzyme-catalysis mechanism and dual cofactor specificity, DicPAH (residues 1-415) was purified and crystallized for structural analysis. Three-dimensional structures of DicPAH will provide a deeper understanding of the cofactor specificity of the hydroxylase reaction and its regulatory properties.
Experimental

Protein expression and purification
DicPAH (residues 1-415; DicPAHÁ415) was cloned into the bacterial expression vector pProEx HTa (Life Technologies, Carlsbad, California, USA) to produce a recombinant protein with an N-terminal hexahistidine tag and a TEV protease cleavage site (MSYYHHHHHHDYDIPTTENLYFQG). Escherichia coli strain BL21 (DE3) was used for protein expression. 100 ml aliquots of an overnight culture were seeded into 1000 ml fresh Luria-Bertani (LB) medium (10 g Bacto tryptone, 5 g yeast extract, 10 g NaCl per litre of solution) containing ampicillin (100 mg ml À1 ) at 310 K with vigorous shaking until the OD 600 reached 0.6. Protein expression was induced for 5 h with 0.4 mM isopropyl -d-1-thiogalactoside (IPTG) at 303 K and cells were harvested by centrifugation (6000 rev min À1 , 6 min, 277 K). The harvested cells were washed with phosphate-buffered saline (PBS; 8 g NaCl, 0.2 g KCl, 1.44 g NaH 2 PO 4 per litre of solution; pH 7.4), resuspended in lysis buffer (50 mM sodium phosphate pH 7.4, 500 mM NaCl, 5 mM imidazole) and disrupted by sonication. After centrifugation (1 h at 12 000 rev min À1 ) at 277 K, the clear supernatant was filtered (qualitative filter paper, Advantec, Japan) and loaded onto an open column of nickel-NTA beads (Qiagen, Hilden, Germany) pre-equilibrated with binding buffer. The column was washed first with ten column volumes of binding buffer and then with ten column volumes of washing buffer (50 mM sodium phosphate pH 7.4, 500 mM NaCl, 20 mM imidazole). The recombinant DicPAHÁ415 was eluted with 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 300 mM imidazole. Fractions containing DicPAHÁ415 were pooled, concentrated and exchanged into 50 mM Tris-HCl pH 8.0, 1 mM EDTA by ultrafiltration (Centriprep YM-50, Millipore, Bedford, Massachusetts, USA). The N-terminal hexahistidine tag was then removed using 0.02 mg TEV protease (Invitrogen, Carlsbad, California, USA) per milligram of protein at 277 K overnight, leaving artifactual residues GAMDPEF at the N-terminus. After removal of the His tag, the DicPAHÁ415 was further purified by anion-exchange chromatography on a Resource 15Q column (GE Healthcare, Piscataway, New Jersey, USA). The protein was eluted using a salt gradient and eluted at $200 mM NaCl pH 7.5. The fractions containing the DicPAHÁ415 protein were finally purified by gelfiltration chromatography on a Superdex 200 column (GE Healthcare, Piscataway, New Jersey, USA) in 20 mM Tris-HCl pH 8.0, 150 mM NaCl. The DicPAHÁ415 protein was pooled and concentrated to 10 mg ml À1 in 20 mM Tris-HCl pH 8.0 by ultrafiltration (Centricon YM-30, Millipore Corporation, Bedford, Massachusetts, USA) for crystallization. The protein purity was examined by SDS-PAGE and native PAGE. The protein concentration was determined using the Bradford assay (Bradford, 1976) .
Crystallization and data collection
Crystallization of apo DicPAHÁ415 was initially carried out using Crystal Screens I and II and Index Screen from Hampton Research (California, USA), Wizard Screens I and II and Cryo Screens I and II from Emerald BioStructures (Bainbridge Island, Washington, USA) and laboratory-made solutions using a microbatch crystallization method at 291 K. Drops containing equal volumes (1 ml) of protein solution (6 mg ml À1 in 20 mM Tris-HCl pH 8.0) and screening solution were equilibrated under Al's oil in a 72-well microbatch plate.
After crystals of apo DicPAHÁ415 were produced from the initial screenings, further screenings to find optimal crystallization conditions were performed using hanging-drop vapour-diffusion trials, varying the pH range, type of precipitant, precipitant concentration and volume of the drop. To obtain crystals of the DicPAHÁ415-BH 2 complex, BH 2 (the oxidized form of BH 4 ) was used as BH 4 is not stable under aerobic conditions. Apo DicPAHÁ415 was incubated with 2 mM BH 2 (Fluka, Steinheim, Switzerland) for 1 h on ice prior to setting up crystallization. The DicPAHÁ415-BH 2 complex crystals grew in the same condition as the apo DicPAHÁ415 crystals. To incorporate Fe III into the protein, the crystals of DicPAHÁ415-BH 2 were soaked in well solution containing 5 mM Fe(NH 4 ) 2 (SO 4 ) 2 (Sigma, Steinheim, Switzerland) for 1 h before flash-freezing. Crystals were flash-frozen in liquid nitrogen for data collection after soaking for 1 min in reservoir solution containing 12%(v/v) ethylene glycol. X-ray diffraction data were collected from apo DicPAHÁ415 Purification of DicPAHÁ415. (a) The purity of the DicPAHÁ415 was confirmed by SDS-PAGE. (b) Analytical gel-filtration chromatography of DicPAHÁ415. A single peak was observed that was estimated using protein standards to correspond to the size of a dimer. The inset shows logK d against log(molecular weight) for protein standards (circles) and DicPAHÁ415 (filled circle). K d was calculated from the equation K d = (V e À V 0 )/(V t À V 0 ), where V e , V t and V 0 represent the eluted volume, total volume and void volume, respectively. The standard proteins were ferritin (440 kDa), aldolase (158 kDa), BSA (67 kDa), ovalbumin (43 kDa), chymotrypsinogen A (25 kDa) and cytochrome c (12.4 kDa).
and DicPAHÁ415-BH 2 -Fe III crystals using an ADSC Quantum 210 CCD detector with X-rays of wavelength 1.23985 Å on beamlines 4A and 6C1 of Pohang Accelerator Laboratory (PAL), Pohang, Republic of Korea, with exposure times of 30 s and 10 s for 1 oscillations at crystal-to-detector distances of 200 and 150 nm, respectively. All diffraction data were indexed, integrated and scaled using HKL-2000 (Otwinowski & Minor, 1997) . Molecular replacement was performed using the program AMoRe (Collaborative Computational Project, Number 4, 1994; Navaza, 2001 ).
Results
Residues 1-415 of D. discoideum PAH (DicPAHÁ415), corresponding to the N-terminal regulatory and central catalytic domains, were expressed in E. coli and purified for crystallization by nickelaffinity, ion-exchange and gel-filtration chromatography. The molecular weight of the protein was estimated to be about 48 kDa from SDS-PAGE, which is similar to the theoretical molecular weight of 47.5 kDa (Fig. 1a) . The protein was separated by gel-filtration chromatography with an effective mass of 80 kDa, suggesting that the protein exists as a dimer in solution (Fig. 1b) . From the initial crystallization trials, dendritic apo DicPAHÁ415 crystals were found using the screening solution 0.1 M PIPES pH 6.5, 30%(w/v) PEG 4000 ( Fig. 2a) . Apo DicPAHÁ415 crystals that were suitable for diffraction experiments were obtained by the hanging-drop vapourdiffusion method at 291 K in a drop containing 5 ml 6 mg ml À1 protein solution and 5 ml of a mixture of 9 ml reservoir solution [0.06 M PIPES pH 7.0, 26%(w/v) PEG 2000] and 1 ml 0.1 M l-proline as an additive. The crystals grew to maximum dimensions of 0.3 Â 0.4 Â 0.2 mm in 3-4 d (Figs. 2b and 2c ). Data were collected to 2.6 Å resolution from a single crystal of apo DicPAHÁ415 and were processed in the monoclinic space group P2 1 , with unit-cell parameters a = 70.02, b = 85.43, c = 74.86 Å , = 110.12 (Table 1) . DicPAHÁ415-BH 2 complex crystals were obtained using the same condition as the apo DicPAHÁ415 crystals and grew to maximum dimensions of 0.3 Â 0.3 Â 0.3 mm in 3-4 d (Fig. 2d) DicPAHÁ415-BH 2 -Fe III complex were produced by soaking the DicPAHÁ415-BH 2 complex crystals. The DicPAH-BH 2 -Fe III complex crystal diffracted to 2.07 Å resolution and belonged to space group P2 1 , with unit-cell parameters a = 70.97, b = 85.33, c = 74.89 Å , = 110.23 (Table 1) . For both crystal forms it was clear that higher resolution data were available and we plan to collect these data as soon as possible. The asymmetric unit contained two DicPAHÁ415 molecules, with a Matthews coefficient V M of 2.24 Å 3 Da À1 and an estimated solvent content of 45.23% (Matthews, 1968) . The crystal of the DicPAHÁ415-BH2-Fe III complex had essentially the same Matthews coefficient and therefore the same number of molecules in the asymmetric unit and the same percentage solvent content. The structure of DicPAHÁ415 could be determined by molecular replacement using the program AMoRe (Collaborative Computational Project, Number 4, 1994; Navaza, 2001) . The human PAH catalytic domain (PDB code 1j8u; Andersen et al., 2001) was used as a search model for molecular replacement, as it shares 64% amino-acid sequence identity in the catalytic domain. After a rotation and translation search, a solution consisting of two catalytic domains with a correlation coefficient of 33.3 and an R factor of 52.2% could be found and was refined to a correlation coefficient of 53.8 and an R factor of 45.7% using the fitting function in AMoRe. The missing N-terminal regulatory domain could be built into the electron densities calculated from the molecular-replacement solution (data not shown). Detailed discussion of the refined structures of both crystals will be published elsewhere.
